Novo Nordisk reports successful Saxenda study

5 April 2016

Data from a three-year trial of Novo Nordisk’s (NOV: N) obesity drug Saxenda (liraglutide injection) have shown positive results.

The SCALE study of 2,254 adults with obesity or who were overweight with co-morbidities and had pre-diabetes at baseline found significant improvements in cardiometabolic risk factors like blood pressure and cholesterol compared with placebo. Both groups were on calorie-reduced diets and increased activity plans.

Also, individuals treated with Saxenda had lost more weight (6.1%) than those treated with placebo (1.9%).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK